Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.47 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4949681 | 0.92 | CA2 (0.43) | CA2CA1CA9CA7CA13 | |
| SCHEMBL4949086 | 0.92 | CA2 (0.43) | CA2CA1CA9CA7CA13 | |
| SCHEMBL4953881 | 0.92 | CA2 (0.43) | CA2CA1CA9CA7CA13 | |
| SCHEMBL575713 | 0.88 | CA2 (0.44) | CA2CA1CA9CA7 | |
| SCHEMBL576009 | 0.88 | CA2 (0.44) | CA2CA1CA9CA7CA13 | |
| Ethane Dimethane Sulfonate SCHEMBL8875130 | 0.87 | USP2 (0.50) | CA2CA1CA9 | |
| SCHEMBL1759185 | 0.87 | CA2 (0.41) | CA2CA1CA9 | |
| SCHEMBL1191830 | 0.87 | CA2 (0.41) | CA2CA1CA9 | |
| SCHEMBL1759184 | 0.87 | CA2 (0.41) | CA2CA1CA9 | |
| SCHEMBL17491815 | 0.87 | CA2 (0.41) | CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200388882-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FLUORINATED ELECTROLYTE FORMULATIONS | ENEVATE CORPORATION | 2020-12-10 | — | — | US | claimed |
| CN-111349027-A | Synthesis method of 1, 2-bis [ (trifluoromethyl) sulfonyloxy ] ethane | 石家庄圣泰化工有限公司 | 2020-06-30 | — | — | CN | claimed |
| US-12531269-B2 | Silicon-based energy storage devices with fluorinated electrolyte formulations | ENEVATE CORPORATION (US) | 2026-01-20 | — | — | US | disclosed |
| US-12049466-B2 | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| EP-3793997-B1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-116706178-A | Aqueous flow battery based on ferrocene derivative electrolyte | 西湖大学 | 2023-09-05 | — | — | CN | disclosed |
| CN-115911573-A | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery using same | 三菱化学株式会社 | 2023-04-04 | — | — | CN | disclosed |
| US-20210198263-A1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| EP-3814325-A1 | A RADIOLABELLED COMPOUND OF QUATERNARY AMMONIUM SALT OF A POLYCYCLIC AROMATIC AMINE, THE USE OF THE RADIOLABELLED COMPOUND IN A DIAGNOSTIC METHOD OF POSITRON EMISSION TOMOGRAPHY, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE RADIOLABELLED COMPOUND OF QUATERNARY AMMONIUM SALT OF A POLYCYCLIC AROMATIC AMINE | Synektik S.A. (PL) | 2021-05-05 | — | — | EP | disclosed |
| EP-3793997-A1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | Forma Therapeutics, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20200388882-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FLUORINATED ELECTROLYTE FORMULATIONS | ENEVATE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| WO-2004052945-A1 | ORGANOMETALLIC TRANSITION METAL COMPOUND, BISCYCLOPENTADIENYL LIGAND SYSTEM, CATALYST SYSTEM AND PROCESS FOR PREPARING POLYOLEFINS | BASELL POLYOLEFINE GMBH (DE) | 2004-06-24 | — | — | WO | disclosed |
| US-20030199703-A1 | Method for producing alkyl-bridged ligand systems and transition metal compounds | EQUISTAR CHEMICALS, LP | 2003-10-23 | — | — | US | disclosed |
| EP-1313747-A1 | METHOD FOR PRODUCING ALKYL-BRIDGED LIGAND SYSTEMS AND TRANSITION METAL COMPOUNDS | Basell Polypropylen GmbH (DE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002018397-A1 | METHOD FOR PRODUCING ALKYL-BRIDGED LIGAND SYSTEMS AND TRANSITION METAL COMPOUNDS | BASELL POLYPROPYLEN GMBH (DE) | 2002-03-07 | — | — | WO | disclosed |
| US-5847126-A | N-azinyl-N'-(het) arylsulphonyl-ureas | BAYER AKTIENGESELLSCHAFT (DE) | 1998-12-08 | — | — | US | disclosed |
| EP-0645386-B1 | N-Azinyl-N'-(het)arylsulfonylureas as herbicides | BAYER AG (DE) | 1997-12-29 | — | — | EP | disclosed |
| US-5580842-A | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-12-03 | — | — | US | disclosed |
| US-5476936-A | Herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 1995-12-19 | — | — | US | disclosed |
| EP-0645386-A1 | N-Azinyl-N'-(het)arylsulfonylureas as herbicides | BAYER AG (DE) | 1995-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12531269-B2 | Silicon-based energy storage devices with fluorinated electrolyte formulations | SLC9A2, SLC9A1, HCN2 | CA2 4/4885CA1 53/4885CA9 79/4885 |
| US-20210198263-A1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | USP30, UCHL1, ADRM1 | CA2 4268/4885CA1 2453/4885CA9 4274/4885 |
| US-20030199703-A1 | Method for producing alkyl-bridged ligand systems and transition metal compounds | ABL1, ICMT, ORAI2 | CA2 1949/4885CA1 3370/4885CA9 1697/4885 |
| US-12049466-B2 | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | USP30, UCHL1, ADRM1 | CA2 4268/4885CA1 2453/4885CA9 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.